Ignite Creation Date:
2025-12-26 @ 5:19 PM
Ignite Modification Date:
2026-01-22 @ 8:12 AM
Study NCT ID:
NCT06846606
Status:
RECRUITING
Last Update Posted:
2025-11-18
First Post:
2025-02-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Sponsor:
Auron Therapeutics, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsed Acute Myeloid Leukemia (AML) | View |
| None | Refractory Acute Myeloid Leukemia (AML) | View |
| None | Relapsed/Refractory AML | View |
| None | Relapsed Myelodysplastic Syndromes | View |
| None | Refractory Myelodysplastic Syndromes | View |
| None | Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | AUTX-703 | View |
| None | Relapsed Acute Myeloid Leukemia | View |
| None | Refractory Acute Myeloid Leukemia | View |
| None | Relapsed/Refractory AML | View |
| None | Acute Myeloid Leukemia | View |
| None | Relapsed Myelodysplastic Syndromes | View |
| None | Refractory Myelodysplastic Syndromes | View |
| None | KAT2A/B degrader | View |
| None | Myelodysplastic Syndromes | View |